Geode Capital Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Geode Capital Management LLC bought a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 13,984 shares of the company’s stock, valued at approximately $343,000. Geode Capital Management LLC owned approximately 1.16% of Oruka Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ORKA. The Manufacturers Life Insurance Company purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $1,037,000. Wellington Management Group LLP bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth $2,013,000. Janus Henderson Group PLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth $5,840,000. Redmile Group LLC bought a new stake in Oruka Therapeutics in the third quarter worth $10,091,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in Oruka Therapeutics in the third quarter worth $11,699,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Trading Down 17.3 %

Shares of NASDAQ ORKA opened at $15.72 on Monday. The stock has a fifty day moving average price of $21.72. The stock has a market capitalization of $550.18 million, a PE ratio of -2.51 and a beta of 0.81. Oruka Therapeutics, Inc. has a 1 year low of $15.63 and a 1 year high of $53.88.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. Lifesci Capital initiated coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. TD Cowen assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, December 20th. Finally, Leerink Partners assumed coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.